» Download Public Reports
About 1 500 reports
- Company report
- April 2013
- 2 pages
... Terry fox: the feature film is the realization of a lifelong dream. Her father, an adidas executive, was the recipient of the letter that terry wrote to secure support of running shoes. Slattery says ...
March 2013
... Available for the early detection of heart attack, congestive heart failure, flu a + b and rsv. In the non-clinical market, ramp tests are currently available for the environmental detection of west nile ...
March 2013
... From 354-square-foot studio apartments for those with mental illness, to 1,608- square-foot, four-bedroom apartments for people with brain injuries. After years of design, fundraising and political ...
April 2013
... Product cands, and the timing and amount of any available investment tax credits, the actual or perceived benefits to users of our drug delivery technologies and product cands as compared ...
April 2013
... Formulated diclofenac by thermis. Top international stories positive data from vertex S cystic fibrosis drug:- boston-based vertex pharmaceuticals has reported positive data from a phase-2 clinical trial ...
April 2013
... Of additional quantities of lor-253, increased clinical costs associated with the lor-253 phase i clinical trial as well as spending on our il-17e and lor-500 programs initiated and escalated in the current ...
April 2013
... breast cancer. It is reported that up to 30% of her2+ breast cancer patients develop brain metastasis for which therapeutic options are limited. Because of its ability to cross the blood-brain barrier ...
April 2013
... Med 2006;38:52-63 these features lead to type 2 diabetes and cardiovascular disease visceral obesity is associated with a cluster of metabolic abnormalities often described as the Metabolic syndrome ...
May 2013
... To production interruptions and diminished capacity Economic choices are made where older, less profitable drugs are eliminated as new generics come to market By year-end 2012, we will see $34b in new ...
April 2013
... Outcomes Risk time Outcome smoking Cancer, cvd, stroke overweight/obesity Cvd, stroke, diabetes, cancer, mental illness alcohol abuse Cvd, cancer, mental illness, injury where does information ...
» Purchase Premium Reports
(From $ 125 - $ 4 995)
About 500 reports
- $ 4 995
- Industry report
- March 2013
- by Global Data
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, ?PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and ...
March 2013
$ 4 950
This report analyzes the worldwide markets for Herbal Supplements and Remedies in US$ Million by the following Product Segments: Ginkgo Biloba, Garlic, Ginseng, Echinacea, St. John's Wort, Soy, Aloe Vera, ...
March 2013
$ 3 495
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Avonex (Multiple Sclerosis) - Forecast and Market Analysis ...
March 2013
$ 3 495
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Tysabri (Multiple Sclerosis) - Forecast and Market Analysis ...
March 2013
$ 3 495
Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Betaseron/Betaferon (Multiple Sclerosis) ...
March 2013
$ 3 495
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Rebif (Multiple Sclerosis) - Forecast and Market Analysis ...
March 2013
$ 3 495
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Gilenya (Multiple Sclerosis) - Forecast and Market Analysis ...
